comparing glp-1 agonists Ozempic, Wegovy and Other Drugs PDB-101: Molecule of the Month:

The company made this prediction on the timing of FDA approval as it announced top-line results of a Phase 3 study showing a nearly 16% overall weight loss over a 17-month period among people who have both Type 2 diabetes and obesity 1

Patoulias D, Boulmpou A, Papadopoulos CE, Doumas M

Research chemical vendors sometimes list compounds under investigational names, but without regulatory oversight, independent third-party testing, and pharmaceutical-grade manufacturing standards, there is no way to verify what you are actually receiving

Vincent HK, Taylor AG

The program will run between July 1, 2026, and December 31, 2027

When functioning normally, it sends signals to your brain that say "you are full" after eating